Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/104697STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE
WO 28.05.2020
Int.Class C07H 17/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
Appl.No PCT/EP2019/082331 Applicant VAXXILON AG Inventor EMMADI, Madhu
The present invention relates to a synthetic saccharide of general formula (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.
2.WO/2020/106627C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF
WO 28.05.2020
Int.Class A61P 31/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
Appl.No PCT/US2019/062030 Applicant ZIKANI THERAPEUTICS, INC. Inventor CLARK, Roger B.
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13- membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides. Formula (I)
3.WO/2020/103916SEPARATION AND PURIFICATION METHOD FOR URIDINE TRIPHOSPHATE
WO 28.05.2020
Int.Class C07H 19/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
10with the saccharide radical being esterified by phosphoric or polyphosphoric acids
Appl.No PCT/CN2019/120049 Applicant SUZHOU NANOMICRO TECHNOLOGY COMPANY LIMITED Inventor JIANG, Biwang Jack
Provided is a separation and purification method for uridine triphosphate. The separation and purification method comprises the following steps: 1) loading: filtering crude uridine triphosphate and then loading same into a chromatography column, wherein the packing of the chromatography column is monodisperse microspheres with polyacrylate as a matrix; 2) eluting: eluting UTP adsorbed in the chromatography column with an eluate; and 3) collecting and gathering: collecting the eluted uridine triphosphate solution in sections, and gathering component solutions that meet the target peak requirements. The separation and purification method for uridine triphosphate of the present invention is simple and convenient, has a short purification cycle, and can satisfy the high purity requirement of uridine triphosphate by means of only one step of chromatography purification. The uridine triphosphate has a purity of 99.9% or more and a high and stable purification yield.
4.WO/2020/106636C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF
WO 28.05.2020
Int.Class C07H 17/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
08Hetero rings containing eight or more ring members, e.g. erythromycins
Appl.No PCT/US2019/062045 Applicant ZIKANI THERAPEUTICS, INC. Inventor CLARK, Roger B.
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13- membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13- membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides.
5.WO/2020/104335ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
WO 28.05.2020
Int.Class C07H 19/056
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
056Triazole or tetrazole radicals
Appl.No PCT/EP2019/081539 Applicant GALECTO BIOTECH AB Inventor ZETTERBERG, Fredrik
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
6.WO/2020/105054MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME
WO 28.05.2020
Int.Class C07H 15/222
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
20Carbocyclic rings
22Cyclohexane rings, substituted by nitrogen atoms
222Cyclohexane rings, substituted by at least two nitrogen atoms
Appl.No PCT/IL2019/051277 Applicant TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED Inventor BAASOV, Timor
Modified aminoglycoside compounds represented by Formula I as defined and described in the specification are provided. The modified aminoglycosides feature a diamine-containing functional moiety at one or more of positions 3', 4' and 6'. Uses of the modified aminoglycosides as antimicrobial (e.g., antibacterial) agents, and in treating medical conditions associated with microorganisms, are also provided.
7.WO/2020/107013ORALLY ACTIVE PRODRUG OF GEMCITABINE
WO 28.05.2020
Int.Class C07H 19/073
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
073with 2-deoxyribosyl as the saccharide radical
Appl.No PCT/US2019/062747 Applicant BLUEVALLEY PHARMACEUTICAL LLC Inventor LI, Xiang
The disclosure includes compounds of Formula (I): wherein R1, R2, and R3, are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.
8.WO/2020/104492PYRIDINIUM SALTS AS ACTIVATORS IN THE SYNTHESIS OF STEREODEFINED OLIGONUCLEOTIDES
WO 28.05.2020
Int.Class C07H 1/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
1Processes for the preparation of sugar derivatives
02Phosphorylation
Appl.No PCT/EP2019/081864 Applicant ROCHE INNOVATION CENTER COPENHAGEN A/S Inventor HANSEN, Dennis Jul
The present invention relates to a method for preparing stereodefined phosphorothioate oligonucleotides, especially locked stereodefined phosphorothioate oligonucleotides with a high yield, using pyridinium acidic salts as a coupling activator.
9.WO/2020/102910POTENTIATION OF β-LACTAM ANTIBIOTICS AND β-LACTAM/β-LACTAMASE INHIBITOR COMBINATIONS AGAINST MULTIDRUG AND EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA USING NON-RIBOSOMAL TOBRAMYCIN-CYCLAM CONJUGATES
WO 28.05.2020
Int.Class C07H 15/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
26Acyclic or carbocyclic radicals, substituted by hetero rings
Appl.No PCT/CA2019/051675 Applicant UNIVERSITY OF MANITOBA Inventor SCHWEIZER, Frank
Herein, we describe the development of non-β-lactam-based potentiator molecules that synergize with β-lactam antibiotics and β-lactam-β-lactamase inhibitor combinations against MDR/XDR P. aeruginosa phenotypes. The compound comprises a chemical structure or chemical formula of Formula (A) or a suitable salt form thereof, wherein "n" is a carbon tether having a length of between about 2-18 carbons.
10.WO/2020/102980PREPARATION METHOD FOR NUCLEOTIDE FOR SEQUENCING
WO 28.05.2020
Int.Class C07H 19/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Appl.No PCT/CN2018/116454 Applicant BGI SHENZHEN Inventor WANG, Wenjin
Proposed is a preparation method for a nucleotide for sequencing, i.e. a preparation method for a compound represented by formula (I), comprising (1) performing a first nucleophilic substitution reaction on a compound represented by formula (II) and a first phosphorylation reagent, the first phosphorylation agent being phosphorus oxychloride; (2) performing a second nucleophilic substitution reaction on the first nucleophilic substitution reaction product and a second phosphorylation agent, so as to obtain a compound represented by formula (I), the second phosphorylation agent being different from the first phosphorylation agent. R1 is H or OH, Base is adenine, guanine, cytosine, thymine or uracil, and R2 is H or a fluorescent label.